Explore the genome-scale CD4+ T cell perturbseq dataset to identify insights for pMHC platform development and investigate potential CCL26/POSTN related findings that could inform therapeutic targets.

This session aimed to mine a genome-scale CD4+ T cell perturb-seq dataset for insights relevant to pMHC platform development, with a specific eye toward CCL26/POSTN-related findings that could inform therapeutic targets in eosinophilic esophagitis (EoE).

The agent processed differential expression readouts from the perturb-seq screen (de_readout_long.parquet, de_qc_summary.csv) and organized findings into two parallel analysis tracks, "programA" (apparently focused on Th2 dampening targets) and "programB" (apparently focused on tolerance/reprogramming amenability and co-targets), each producing consolidated result tables, heatmaps, and figures (fig1_readout_coverage, fig2_programA_dampeners, fig3_programB_amenability, fig4_integration, fig5_druggability). It also incorporated target druggability and localization annotations (target_druggability_classification.csv, uniprot_localization_top.csv, candidates_annotated.csv) and compiled the results into written deliverables, including a reprogramming target report/brief and an integrated business-scientific report, alongside supporting pipeline diagrams and simple web/HTML assets. No final agent message was recorded, so the session's concluding interpretation or explicit findings on CCL26/POSTN are not captured in the available metadata.

Key deliverables include the Tolera_Reprogramming_Target_Report.pdf and EoE_Integrated_Business_Scientific_Report.pdf as primary written summaries, supported by program-level data tables (programA_consolidated_full.csv, programB_consolidated_full.csv, programA_th2_dampening_targets.csv, programB_tolerance_amenability_cotargets.csv) and visualizations (programA_heatmap.png, programB_heatmap.png, fig1–fig5 series), plus a program_verdicts.json capturing evaluated conclusions.